XML 20 R9.htm IDEA: XBRL DOCUMENT v3.22.2
Revenues
 6 Months Ended
Jun. 30, 2022
Segment Reporting [Abstract]  
REVENUES REVENUES
Product Revenues
The Company accounts for revenues from contracts with customers under ASC 606, which became effective January 1, 2018.
The Company’s net revenues consisted of the following for the three and six months ended June 30, 2022 and 2021:
Three months ended June 30,Six months ended June 30,
2022202120222021
Products:
Kristalose$3,570,272 $5,275,065 $7,515,368 $8,269,443 
Sancuso3,398,548 — 6,795,758 — 
Vibativ1,596,821 1,844,936 4,098,255 6,897,179 
Caldolor1,193,916 938,328 2,153,546 2,477,824 
Vaprisol(134,621)399,952 (251,623)1,534,216 
Acetadote126,789 152,781 237,884 269,972 
Omeclamox-Pak(26,412)(24,109)(3,676)(474,371)
RediTrex93,676 7,382 152,904 (24,870)
Other revenue480,163 461,148 775,781 643,249 
Total net revenues$10,299,152 $9,055,483 $21,474,197 $19,592,642 
The Omeclamox-Pak revenue for the second quarter of 2022 and 2021 was the result of Cumberland currently being out of commercial inventory of this product. The packager for our Omeclamox-Pak product encountered financial difficulties due to the impact of COVID-19. They are under new management and are in the process of a reorganization. Discussions with the packager are ongoing. In the second quarter of 2022, the amounts noted were normal adjustments by channel partners. Net revenue was impacted by product return adjustments.
With regard to Vaprisol, we are in the process of transitioning to a new manufacturer, who was issued an FDA Form 483 in the second quarter of 2022. Once these 483 related issues are satisfactorily resolved by the manufacturing plant, we will then resubmit our application to the FDA for approval. Net revenue was impacted by product return adjustments.
Other Revenues
The Company has agreements with international partners for commercialization of the Company's products with associated payments included in other revenues. Those agreements provide that each of the partners are responsible for seeking regulatory approvals for the product, and following approval, each partner will be responsible for the ongoing distribution and sales in the respective international territories. The Company provides a dossier for product registration and maintains responsibility for the relevant intellectual property. Cumberland is typically entitled to receive a non-refundable, up-front payment at the time each agreement is executed as consideration for the product dossier and for the rights to the distinct intellectual property rights in the respective international territory. These agreements also typically provide for additional payments upon a partner’s achievement of a defined regulatory approval and sales milestones. The Company may also be entitled to receive royalties on future sales of the products and a transfer price on supplies. The contractual payments associated with the partner’s achievement of regulatory approvals, sales milestones and royalties on future sales are recognized as revenue upon occurrence, or at such time that the Company has a high degree of confidence that the revenue would not be reversed in a subsequent period.
During the three and six months ended June 30, 2022, we recorded $0.3 million and $0.5 million, respectively, for milestone and international licensee payments as part of other revenue.
Other revenues also include funding from federal grant programs including those secured from the FDA and from those secured by Cumberland Emerging Technologies Inc. ("CET") through the Small Business Administration as well as lease income generated by CET’s Life Sciences Center. The Life Sciences Center is a research center that provides scientists with access to flexible lab space and other resources to develop biomedical products. Grant revenue from these federal grant programs totaled approximately $0.04 million and $0.3 million for the three months ended June 30, 2022 and 2021, and approximately $0.08 million and $0.3 million for the six months ended June 30, 2022 and 2021, respectively.